The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)

Inclusion Criteria: * Adult patients, greater than 18 years old. * Surgically confirmed diagnosis of malignant glioma, specifically anaplastic glioma (anaplastic astrocytoma \[AA\], anaplastic oligodendroglioma \[AO\], anaplastic oligoastrocytoma \[AOA\]) or glioblastoma multiforme (GBM). * Must have completed at least 2 cycles (2 months) of conventional 5/28 temozolomide, with radiological evidence of progression. * GBM treated with concurrent chemoradiation with temozolomide according to the EORTC/NCIC (European Organization for Research \& Treatment of Cancer/National Cancer Institute of Canada) protocol. * Evidence of progression confirmed radiologically (CT \[computed tomography\] or MRI \[magnetic resonance imaging\]). * Patients must be enrolled within 2 weeks of last radiological confirmation of progression, except for patients undergoing surgical resection. * Patients undergoing surgical resection for recurrent disease must be enrolled within 2 weeks of the post-surgical scan. * Patients with no residual disease after surgery are allowed. * Steroids dose should have been stabilized during the last 2 weeks prior to enrollment. * Use of medically approved contraception in fertile males and females. * Women of childbearing potential must have a negative urine or serum pregnancy test (urinary excretion or serum level of bHCG \[beta human chorionic gonadotropin\]) within 24 hours of inclusion in the study. * Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. * Signed informed consent form. Exclusion Criteria: * GBM progression during the first 2 months of adjuvant temozolomide (5/28). * AA progression during the first 2 months of standard temozolomide therapy (5/28). * Chemotherapy for the malignant glioma other than temozolomide. * More than one prior course of chemotherapy with temozolomide. * Patient evolving from anaplastic glioma to GBM following primary therapy. * Patient older than 70 years or who received no conventional chemoradiation regimen. * Patient who received radiotherapy for recurrent disease. * Patient with metastatic disease. * Known human immunodeficiency virus (HIV) infection. * History of non-compliance to other therapies. * Inadequate hematological, renal and hepatic function according to all of the following laboratory values (to be performed within 14 days, inclusive, prior to study inclusion): * Absolute neutrophil count \<=1.5 ×10\^9/L; * Platelets \<=100 ×10\^9/L; * Hemoglobin \<90 g/L; * Serum creatinine \>=1.5 times upper limit of laboratory normal (ULN); * Total serum bilirubin \>=1.5 times ULN; * ASAT (AST \[aspartate aminotransferase\]) or ALAT (ALT \[alanine aminotransferase) \>2.0 times ULN; * Alkaline phosphatase of \>2.5 times ULN. * Known chronic hepatitis B or hepatitis C infection. * Any other serious medical condition, according to the medical judgment of the physician prior to inclusion in the study. * Any medical condition that could interfere with oral medication intake (e.g., frequent vomiting, partial bowel obstruction). * Other malignancies during the previous 5 years with the exception of surgically cured carcinoma in-situ of the cervix and basal cell carcinoma or non-melanoma skin cancer. * Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule as discussed with the patient before inclusion in the study.